Drug Safety Alert: Indian Pharmacopoeia Commission Flags ADR Linked To Ceftriaxone,Levosulpiride

This came after a preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Ceftriaxone is a broad-spectrum cephalosporin antibiotic used for the treatment of bacterial infections in various locations, such as in the respiratory tract, skin, soft tissue, and urinary tract.

Ceftriaxone works by inhibiting mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. The binding of ceftriaxone to these enzymes causes the enzyme to lose activity; therefore, the bacteria produce defective cell walls, causing cell death.

On the other hand, Levosulpiride, sold under the brand name Neoprad, is a typical antipsychotic and a prokinetic agent of the benzamide class. It is a selective antagonist of the dopamine D2 receptors in both central and peripheral nervous systems. Levosulpiride is claimed to have mood-elevating properties.

Following the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database, it is reported that Ceftriaxone causes a prolonged QT interval. QT prolongation occurs when the heart muscle takes longer to contract and relax than usual. Various health factors and medications can increase the risk. QT prolongation can affect heart rhythms and lead to sudden cardiac arrest.

Additionally, preliminary research on Adverse Drug Reactions (ADRs) from the PvPI database indicates that Levosulpiride may lead to Restless Legs Syndrome (RLS). Restless legs syndrome (RLS) is a neurological disorder that causes unpleasant or uncomfortable sensations in legs and an irresistible urge to move them.

Now, as per the issued drug safety alert, the following suspected drug is associated with the ADRs as given below:

In light of the above, the Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, has advised Healthcare Professionals, Patients/Consumers to closely monitor the possibility of the above ADRs associated with the use of above suspected drugs.

Further, the safety alert added, "If such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App "ADR PvPI App" and PvPIHelpline No. 1800-180-3024 (Toll Free)."